2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases  American College of Rheumatology      263B6488AC287683F9490992215EE324 10.1002/acr.25045 Submitted for publication August 8, 2022; accepted in revised form October 13, 2022.  INTRODUCTION Rheumatic and musculoskeletal diseases (RMDs) 1 2 Avacopan and bimekizumab, the pneumococcal vaccines PCV15 and PCV20, and the smallpox/monkeypox vaccine were not included in the formal evidence review because they were not approved at the time of the project plan. Antipyretic medications such as nonsteroidal antiinflammatory drugs and acetaminophen were also not included. Although a few randomized controlled trials (RCTs) have demonstrated blunted antibody responses with antipyretics, this was seen after primary vaccination only, and not after booster The 2022 ACR guideline for vaccination in adults and children with RMDs highlights the following: 1) pneumococcal vaccination